Verastem, Inc. 10-Q Summary
Business context and reporting period
Verastem is a clinical-stage biopharmaceutical company developing oncology therapies targeting FAK and PI3K/mTOR pathways. Its principal candidates were VS-6063 (defactinib), VS-4718, and VS-5584, evaluated in clinical or preclinical studies for cancers including ovarian, pancreatic, lung, lymphoma, and mesothelioma. The filing covers the three months ended March 31, 2016, and the financial statements are unaudited. The company had not generated revenue.
Financial condition and key metrics
| Metric | Q1 2016 | Q1 2015 / March 31, 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.2 million | $10.5 million |
| General and administrative expense | $4.3 million | $4.7 million |
| Total operating expenses | $8.4 million | $15.2 million |
| Net loss | $8.3 million | $15.2 million |
| Net loss per share | $0.22 | $0.46 |
| Net cash used in operating activities | $10.8 million | $11.7 million |
| Cash, cash equivalents and investments | $99.5 million | $110.3 million at December 31, 2015 |
| Debt | The filing does not report debt |
At March 31, 2016, cash and cash equivalents were $15.1 million and short-term investments were $84.4 million. Total assets were $102.6 million, total liabilities were approximately $6.6 million, and stockholders’ equity was $96.0 million. The company reported an accumulated deficit of $207.2 million.
Interest income increased to $140,000 from $62,000. Comprehensive loss was $8.2 million, including a $92,000 unrealized gain on available-for-sale securities. The company stated that its investment portfolio consisted primarily of U.S. Treasury and government-sponsored enterprise securities, corporate bonds, and commercial paper.
Material changes versus the prior comparable period
- Research and development expense declined $6.3 million, primarily due to lower CRO costs, reduced personnel costs following the 2015 workforce reduction, and lower stock-based compensation.
- VS-6063 program spending declined to $1.5 million from $5.2 million; VS-4718 spending declined to $460,000 from $537,000; and VS-5584 spending declined to $372,000 from $850,000.
- General and administrative expense decreased approximately $400,000, primarily from lower stock-based compensation and personnel costs, partly offset by higher consulting and professional fees.
- Net loss improved by $6.9 million, while operating cash use improved by approximately $905,000.
- Q1 2015 included substantial equity financing proceeds of $55.6 million; Q1 2016 had no equity issuance proceeds and cash decreased by $9.7 million.
- Investing activities provided $1.1 million in Q1 2016, principally from net investment maturities, compared with $47.4 million of cash used in Q1 2015 for net investment purchases.
Guidance, outlook, risks, contingencies, and unusual items
Management expected existing cash, cash equivalents, and investments to fund the current operating plan and capital expenditure requirements into 2018. This estimate depends on assumptions that may prove incorrect, and the company could use its capital sooner than expected. The company had no committed external source of funds and expected to require substantial additional financing.
Management expected significant expenses and operating losses to continue, particularly as clinical trials progress. Future funding may come from equity or debt financings, collaborations, strategic alliances, or licensing arrangements. Additional equity financing could dilute existing stockholders; debt financing could impose restrictive covenants; and strategic transactions could require the company to relinquish rights to technologies or product candidates.
The October 2015 reduction in force reduced the workforce by approximately 50% to 20 full-time employees. Management estimated annual cash operating expense savings of approximately $5.1 million and one-time severance and related costs of $1.1 million. Approximately $521,000 was paid in Q1 2016, with approximately $192,000 remaining to be paid.
Key development risks include clinical-trial enrollment and outcomes, unexpected safety events, regulatory approval, intellectual-property protection, reliance on third parties, competition, and the ability to raise capital. The filing states that there were no material changes to the risk factors in the prior Form 10-K, no legal proceedings, and no off-balance-sheet arrangements.
Subsequent to quarter-end, Gregory Berk became Chief Medical Officer and John Green resigned as Chief Financial Officer, effective April 15, 2016. Joe Chiapponi was appointed treasurer, principal financial officer, and principal accounting officer effective April 18, 2016.
Important facts for investors to verify
- Whether clinical data for VS-6063, VS-4718, and VS-5584 support continued development and planned regulatory milestones.
- Whether the stated cash runway through 2018 remains achievable under updated trial schedules, enrollment rates, and spending levels.
- The timing, size, and terms of any future equity, debt, collaboration, or licensing financing.
- The effect of the workforce reduction and remaining severance payments on ongoing clinical and operating capabilities.
- Changes in executive leadership and the terms of the new employment and consulting agreements.
- The company’s ability to generate revenue, since it had no revenue and no approved commercial products as of the filing.